The role of monoamines in the actions of established and “novel” antidepressant agents: a critical review
- 1 October 2004
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 500 (1-3) , 371-384
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- P.1.036 Lack of anti-depressant efficacy of the selective 5-HT1A receptor antagonist NAD-299. Results from an 8-week placebo and paroxetine-controlled studyEuropean Neuropsychopharmacology, 2003
- The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic PathwaysThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range studyInternational Clinical Psychopharmacology, 2002
- Effects of Antidepressants in Rats Trained to Discriminate Centrally Administered IsoproterenolThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Pharmacology of FlibanserinCNS Drug Reviews, 2002
- Potential Antidepressants Displayed Combined α2-Adrenoceptor Antagonist and Monoamine Uptake Inhibitor PropertiesJournal of Medicinal Chemistry, 2001
- Positive modulators of the AMPA receptorExpert Opinion on Therapeutic Patents, 2000
- A review of the role of serotonin receptors in psychiatric disordersHuman Psychopharmacology: Clinical and Experimental, 2000
- NefazodoneDrugs, 1997
- Further Characterization of the Long‐Term Effect of RU24722 on Tyrosine Hydroxylase in the Rat Locus CoeruleusJournal of Neurochemistry, 1993